RxDoctor Payments Data

Jordan Lidsky-Everson, PA

Physician Assistant · Meriden, CTNPI 1508570367

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 95 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$460
  • E.r. Squibb & Sons, L.L.C.$320
  • Bristol Myers Squibb$258
  • Johnson & Johnson$158
  • Daiichi Sankyo Inc.$151
  • Astellas Pharma US Inc$127
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,24583%
  • Education$47217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 90th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,845
Medicare patients
164
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide13$216,826
EliquisApixaban36$29,281
OxycontinOxycodone Hcl12$25,847
Dexamethasone69$1,569
Ondansetron OdtOndansetron109$1,282
Prochlorperazine Maleate101$1,017
Oxycodone Hcl41$711
Lidocaine-PrilocaineLidocaine/Prilocaine51$567
Gabapentin39$491
Olanzapine38$482
Acyclovir20$233
Letrozole12$184
Lorazepam12$111
Famotidine13$102
Nystatin11$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$258$216,82613 claims
PfizerEliquis$87$29,28136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →